Finoriq research workspace
Immunovant, Inc. (IMVT) News
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of. Review IMVT recent headlines, source links, and company news on Finoriq.
Company Snapshot
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
- Company
- Immunovant, Inc. (IMVT)
- Ticker
- IMVT
- Market Cap
- $8.2B
- Latest Price
- $39.91
- Industry
- Biotech & Pharma
Live data loads in the app
This static page shell gives search engines reliable page context. Current tables, filings, charts, and market data continue to load from Finoriq APIs after the application starts.